Pharma-Bio Serv Announces Special Dividend
Pharma-Bio Serv (OTCQB:PBSV), a consulting firm serving pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, has announced a special dividend of $0.075 per share. The company, which specializes in regulatory affairs, quality, compliance, project management and technology transfer support, will distribute the dividend on March 20, 2025 to shareholders of record as of February 28, 2025.
Pharma-Bio Serv (OTCQB:PBSV), una società di consulenza che opera nei settori farmaceutico, biotecnologico, dispositivi medici, cosmetici, alimentari e prodotti affini, ha annunciato un dividendo speciale di 0,075 $ per azione. L'azienda, specializzata in affari regolatori, qualità, conformità, gestione progetti e supporto al trasferimento di tecnologia, distribuirà il dividendo il 20 marzo 2025 agli azionisti registrati al 28 febbraio 2025.
Pharma-Bio Serv (OTCQB:PBSV), una firma de consultoría que presta servicios a las industrias farmacéutica, biotecnológica, de dispositivos médicos, cosméticos, alimentarios y productos afines, ha anunciado un dividendo especial de 0,075 $ por acción. La empresa, que se especializa en asuntos regulatorios, calidad, cumplimiento, gestión de proyectos y soporte de transferencia de tecnología, distribuira el dividendo el 20 de marzo de 2025 a los accionistas registrados hasta el 28 de febrero de 2025.
Pharma-Bio Serv (OTCQB:PBSV)는 제약, 생명공학, 의료기기, 화장품, 식품 및 관련 제품 산업에 서비스를 제공하는 컨설팅 회사로, 특별 배당금을 주당 0.075달러로 발표했습니다. 규제 업무, 품질, 준수, 프로젝트 관리 및 기술 이전 지원 전문 기업인 이 회사는 2025년 3월 20일에 2025년 2월 28일 기준 주주에게 배당금을 지급할 예정입니다.
Pharma-Bio Serv (OTCQB:PBSV), une société de conseil servant les industries pharmaceutique, biotechnologique, des dispositifs médicaux, cosmétique, alimentaire et produits connexes, a annoncé un dividende exceptionnel de 0,075 $ par action. L'entreprise, spécialisée dans les affaires réglementaires, la qualité, la conformité, la gestion de projet et le soutien à la transfert de technologie, distribuera le dividende le 20 mars 2025 aux actionnaires inscrits au 28 février 2025.
Pharma-Bio Serv (OTCQB:PBSV), ein Beratungsunternehmen, das die pharmazeutische, biotechnologische, Medizintechnik-, Kosmetik-, Lebensmittel- und verwandte Branchen bedient, hat eine sonstige Dividende von 0,075 $ pro Aktie angekündigt. Das Unternehmen, das sich auf regulatorische Angelegenheiten, Qualität, Compliance, Projektmanagement und Technologietransfer unterstützt, wird die Dividende am 20. März 2025 an die zum 28. Februar 2025 registrierten Aktionäre auszahlen.
- Special dividend of $0.075 per share announced
- Company has sufficient cash reserves to distribute dividends
- None.
DORADO, PUERTO RICO / ACCESS Newswire / January 29, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a regulatory affairs, quality, compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, medical device, cosmetic, food and allied products industries, today announced that the Board of Directors approved a Special Dividend of
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this news release. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this news release, forward-looking statements are inherently subject to significant business risks, economic uncertainties, competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's most recent Annual Report on Form 10-K, and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the amount of Pharma-Bio Serv's (PBSV) special dividend announced on January 29, 2025?
When is the record date for Pharma-Bio Serv's (PBSV) 2025 special dividend?
When will Pharma-Bio Serv (PBSV) pay its special dividend announced in January 2025?
Who is eligible to receive Pharma-Bio Serv's (PBSV) 2025 special dividend?
